samedan logo
 
 
 
spacer
home > ebr > spring 2003 > the importance of provisional protection for biotech inventions
PUBLICATIONS
European Biopharmaceutical Review

The Importance of Provisional Protection for Biotech Inventions

With the biotech industry developing into a pipeline feeder for the pharmaceutical industry to a certain extent, biotech companies are having to seek new ways of protecting some of their most valuable assets. Provisional protection available under the most important legal systems such as the European Patent Convention, US Patent Act and Japanese Patent Act offer an opportunity which to date has been mostly unexplored.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Armin Bohmann, Founder and Partner of Bohmann & Loosen, and Dr Ulrich Gerth, Vice President of Equity Corporate Finance at Hypovereinsbank Corporates & Markets

Dr Armin K Bohmann is Founder and Partner of Bohmann & Loosen, which was established in August 2000. Armin was previously Head of the Biotech Department of a leading German law firm specialising in intellectual property. His interests are IP matters related to biotechnology, chemistry and pharmacy; including prosecution, litigation and licensing.

Armin received a Diploma in Molecular Biology from the Technical University of Munich and a Doctorate Degree in Bioprocess and Biochemical Engineering, and spent one year as a postdoctoral in Japan.


Dr Ulrich C Gerth is Vice President of Equity Corporate Finance at HVB Corporates & Markets. He joined the company in April 2000, working in the biotech and life sciences sector on technology, products and business models. He moved to the corporate finance department in July 2001.

Ulrich previously worked as a Consultant for Ernst & Young's life sciences team. He was responsible for pre-IPO evaluations, consultation and market research, and was a co-author of two of their European Life Sciences Reports. After gaining a degree in Biochemistry from the University of Witten/Herdecke, Ulrich obtained his doctorate degree in Molecular Medicine at Oxford University, UK.

spacer
Dr Ulrich C Gerth
spacer
spacer
spacer
Dr Armin K Bohmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius Stedim Biotech Launches New Services for Mammalian Cell Bank Manufacturing

GOETTINGEN, Germany and GLASGOW, UK, August 08, 2019 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharmaceutical industry, today announced the launch of new services for mammalian cell bank manufacture under GMP conditions. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced contract testing organization (CTO) based in Glasgow, UK, and in Cambridge, Massachusetts, USA.
More info >>

White Papers
 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement